Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding

Liver International

Volumn 34, Issue 1, 2014, Pages 26-32

  Intagliata, Nicolas M ^a   Henry, Zachary H ^a   Shah, Neeral ^a   Lisman, Ton ^b   Caldwell, Stephen H ^a   Northup, Patrick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bleeding; Cirrhosis; Coagulation; Deep venous; Thrombosis; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; END STAGE LIVER DISEASE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

BLEEDING; CIRRHOSIS; COAGULATION; DEEP VENOUS; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VIRGINIA;

EID: 84890120584     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12211     Document Type: Article

References (35)

1. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-93.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism The Worcester DVT Study. Arch Intern Med 1991; 151: 933-8.
3. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther 2007; 29: 2395-405.
4. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9.
5. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients prophylaxis in medical patients with enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
6. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: american college of chest physicians evidence-based clinical practice guidelines. (8th Edition)Chest 2008; 6(Suppl): 381S-453S.
7. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest 2007; 132: 936-45.
8. Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-8.
9. Garcia-Fuster MJ, Abdilla N, Fabia MJ, et al. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig 2008; 100: 259-62.
10. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008; 53: 3012-7.
11. Sogaard KK, Horvath-Puho E, Gronbaek H, et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96-101.
12. Ali M, Ananthakrishnan AN, McGinley EL, Saeian K. Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci 2011; 56: 2152-9.
13. Aldawood A, Arabi Y, Aljumah A, et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 2011; 9: 1.
14. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol 2010; 8: 800-5.
15. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145-9.
16. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-56.
17. Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 53: 362-71.
18. Northup PG. Hypercoagulation in liver disease. Clin Liver Dis 2009; 13: 109-16.
19. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137: 2105-11.
20. Tripodi A, Primignani M, Chantarangkul V, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124: 132-6.
21. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388-93.
22. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB (Oxford) 2009; 11: 459-64.
23. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691-7.
24. Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44 : 448-51.
25. Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10: 776-83.
26. Senzolo M, T MS, Rossetto V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32: 919-27.
27. Villa E, Camma C, Marietta M, et al. Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients with Advanced Cirrhosis. Gastroenterology 2012; 143: 1253-60.
28. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 6(Suppl): 340S-80S.
29. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139: 69-79.
30. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the S Standardization Committee of the International Society on T Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of thrombosis and haemostasis: JTH 2005; 3: 692-4.
31. Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int 2012; 32: 1465-76.
32. Senzolo M, Ferronato C, Burra P, Sartori MT. Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. Intern Emerg Med 2009; 4: 161-2.
33. Bechmann LP, Sichau M, Wichert M, et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31: 75-82.
34. Vivarelli M, Zanello M, Zanfi C, et al. Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: is it necessary? World J Gastroenterol 2010; 16: 2146-50.
35. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710-5.